What question did this study set out to answer?

To summarize the current treatment landscape and emerging therapeutic strategies for advanced hepatocellular carcinoma.

Systemic Therapy for Advanced Hepatocellular Carcinoma in 2026: Current Standard‐of‐Care and Emerging Therapeutic Strategies

View Full Paper

Ask AI

Bookmark

To summarize the current treatment landscape and emerging therapeutic strategies for advanced hepatocellular carcinoma.
Reviewed recent advancements in immunotherapy and tyrosine kinase inhibitors.
Analyzed Phase 3 randomized studies including EMERALD-1, LEAP-012, and TALENTACE.
Discussed the potential of cellular therapy and locoregional treatments.
Immunotherapy combinations have surpassed TKI as first-line treatment for advanced HCC.
Only 20%-30% of patients respond to first-line immunotherapy; 50% may progress in 6 months.
Combination of TACE with immunotherapy showed survival benefits in recent trials.

No takes yet. Share an insight, caveat, or question.

This review highlights advances in systemic therapies for advanced hepatocellular carcinoma, suggesting better treatment options for patients.

Chan et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

This review highlights advances in systemic therapies for advanced hepatocellular carcinoma, suggesting better treatment options for patients.